SCHEMBL5867083

SCHEMBL5867083

O=C(Cc1ccc(C(=O)O)cc1)NCC1CN(Cc2ccc(Cl)c(Cl)c2)CCO1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 2/20 0.65
DRD4 P21917 6/20 0.52
SIGMAR1 Q99720 3/20 0.50
S1PR5 Q9H228 2/20 0.47
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
HTR1A P08908 1/20 0.46
ADRA2A P08913 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
ADRA2B P18089 1/20 0.46
HTR2C P28335 1/20 0.46
SLC6A4 P31645 1/20 0.46
CYP2C19 P33261 1/20 0.46
DRD3 P35462 1/20 0.46
HTR2B P41595 1/20 0.46
KCNH2 Q12809 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5867033 0.95 CCR3 (0.59) CCR3DRD4SIGMAR1S1PR5CYP1A2
SCHEMBL4024938 0.92 CCR3 (0.62) CCR3DRD4SIGMAR1CYP1A2CYP3A4
SCHEMBL4028498 0.92 CCR3 (0.66) CCR3DRD4SIGMAR1S1PR5CYP1A2
SCHEMBL4024408 0.91 CCR3 (0.78) CCR3DRD4SIGMAR1S1PR5CYP1A2
SCHEMBL5867207 0.91 CCR3 (0.64) CCR3DRD4SIGMAR1S1PR5CYP1A2
SCHEMBL4025737 0.91 CCR3 (0.63) CCR3DRD4SIGMAR1CYP1A2CYP3A4
SCHEMBL4027381 0.91 CCR3 (0.59) CCR3DRD4SIGMAR1S1PR5CYP1A2
SCHEMBL5832363 0.90 CCR3 (0.62) CCR3DRD4SIGMAR1CYP1A2CYP3A4
SCHEMBL5832649 0.90 CCR3 (0.62) CCR3DRD4SIGMAR1S1PR5CYP1A2
SCHEMBL4156918 0.89 CCR3 (0.61) CCR3DRD4SIGMAR1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1324990-B1 MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LTD (GB) 2014-10-29 EP claimed
JP-2006504625-A 2006-02-09 JP claimed
EP-1492537-A1 MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2005-01-05 EP claimed
WO-2003082294-A1 MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-10-09 WO claimed
EP-1492537-A1 MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2005-01-05 EP disclosed
WO-2003082294-A1 MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-10-09 WO disclosed